Chest Infection Antibiotics Online: Can Telehealth Treat a Chest Infection?

A chest infection is one of the most common reasons Australians visit a GP. It is also one of the most commonly mismanaged - in the sense that antibiotics are frequently prescribed when they are not needed, or sought by patients who assume any chest infection is bacterial. Understanding what type of chest infection you likely have, and what clinical features determine whether antibiotics are appropriate, helps you get the right treatment through the right channel.

This is the definitive guide to chest infection telehealth prescribing in Australia: what the doctor assesses, when telehealth will prescribe, and when referral is the right answer.

"Chest infection" is a broad, non-technical term. Clinically, respiratory infections are divided into two categories based on where in the respiratory tract they occur.

**Upper respiratory tract infections (URTIs)** affect the nose, throat, sinuses, and larynx. The cold and flu are URTIs, as is tonsillitis and most sore throats. URTIs are almost always viral and rarely require antibiotics.

**Lower respiratory tract infections (LRTIs)** affect the airways and lung tissue below the larynx - the bronchi, bronchioles, and alveoli. When people say "chest infection," they typically mean an LRTI. The main types are:

**Acute bronchitis** - inflammation of the bronchial airways, producing a productive cough that can last 2-3 weeks. More than 90% of acute bronchitis cases in otherwise healthy adults are caused by viruses. Antibiotic prescribing is not recommended for acute bronchitis in patients without underlying lung disease - a position stated clearly in the Australian Therapeutic Guidelines (eTG Antibiotic). Yet acute bronchitis is one of the most antibiotic-overprescribed conditions in Australian general practice.

**Community-acquired pneumonia (CAP)** - infection of the lung tissue itself, producing systemic illness: fever, rigors, pleuritic chest pain (sharp pain that worsens with breathing), and breathlessness. CAP is typically bacterial and does require antibiotic treatment. S. pneumoniae (pneumococcus) is the most common causative organism for typical CAP.

**Atypical pneumonia** - a subset of pneumonia caused by organisms including Mycoplasma pneumoniae and Chlamydophila pneumoniae. More common in younger adults, with an insidious onset over days to weeks, a persistent non-productive or mildly productive cough, and systemic features that are often milder than typical CAP. Treated differently - standard penicillin-based antibiotics are ineffective.

**Acute exacerbation of COPD (AECOPD)** - in patients with chronic obstructive pulmonary disease, bacterial infection is a common trigger for exacerbations. When purulent (coloured) sputum is present alongside worsening breathlessness and increased cough, antibiotic prescribing is more clearly indicated than in otherwise healthy adults.

This is the most important clinical distinction, and the one most patients get wrong.

The large majority of acute chest infections - including most cases with productive cough, coloured sputum, and chest tightness - are viral. The causative agents include influenza, rhinovirus, respiratory syncytial virus (RSV), and others. Viruses cause the same inflammatory response as bacteria, producing the same yellow or green sputum and the same uncomfortable productive cough. Sputum colour is not a reliable indicator of bacterial infection.

Antibiotics have no effect on viruses. Prescribing amoxicillin for viral bronchitis does not shorten the illness, reduce severity, or prevent bacterial superinfection in otherwise healthy adults. It exposes the patient to side effects, disrupts the gut microbiome, and contributes to antimicrobial resistance at both the individual and population level.

The clinical features that shift the probability toward bacterial infection include:

• Fever above 38.5C with systemic features (rigors, myalgia, prostration) disproportionate to a simple URTI
• Localised chest signs on auscultation (crackles, bronchial breath sounds) - though these require a stethoscope and are not accessible via telehealth
• Symptom progression rather than the typical viral plateau-and-resolve pattern
• Pleuritic chest pain
• Hypoxia or breathlessness beyond what the cough alone would explain
• Specific host factors: COPD, bronchiectasis, significant comorbidities

An AHPRA-registered online doctor reviewing a chest infection request cannot auscultate your chest, measure your oxygen saturation, or order a chest X-ray. Those limitations are real and are a key factor in which presentations are suitable for telehealth versus which require in-person assessment.

What the doctor can assess remotely:

**Symptom duration and pattern.** How long the cough has been present, how it has progressed, and whether it is improving or worsening. Viral bronchitis typically follows a predictable arc. Symptoms worsening beyond day 5-7, or a biphasic pattern (initial improvement then marked deterioration), can suggest bacterial involvement.

**Sputum character.** Not just colour, but volume, consistency, and any change from baseline. In COPD, a change in sputum from clear to purulent alongside worsening breathlessness is a recognised clinical indicator supporting antibiotic use.

**Fever pattern.** High-grade fever (above 38.5C) with rigors suggests a more significant systemic infection. The relationship between fever severity, onset, and respiratory symptoms helps differentiate URTI with cough from LRTI with systemic illness.

**Breathlessness.** Any dyspnoea beyond what the cough itself would explain - difficulty completing sentences, breathlessness at rest - is a red flag that warrants in-person assessment rather than telehealth prescribing.

**Underlying conditions.** COPD, asthma, bronchiectasis, diabetes, heart failure, and immunosuppression all shift both the probability of bacterial infection and the threshold for prescribing. Underlying lung disease makes bacterial LRTI more likely and more serious.

**Smoking history.** Current smokers with productive cough have altered baseline respiratory function and increased susceptibility to bacterial LRTI, particularly during viral illness seasons.

**Age and clinical context.** Age 65 or older, aged care facility residents, and patients with multiple comorbidities have reduced physiological reserve. The CURB-65 tool (Confusion, elevated Urea, Respiratory rate over 30, low Blood pressure, Age 65 or over) is used to guide hospitalisation decisions for CAP - high CURB-65 scores are not appropriate for telehealth management.

**Recent antibiotic use.** Antibiotics in the past 3 months affect which organisms are likely and which antibiotics are likely to be effective.

Telehealth antibiotic prescribing for chest infection is appropriate when the clinical picture suggests bacterial LRTI in a lower-risk patient. Specifically:

**COPD or chronic bronchitis exacerbation with purulent sputum.** Patients with established COPD who develop worsening breathlessness alongside a change in sputum to purulent (yellow or green, increased volume) benefit from antibiotics, per the eTG COPD exacerbation criteria. This is one of the cleaner telehealth indications for chest infection antibiotic prescribing, because the baseline condition is known and the prescribing criteria are symptom-based.

**Clinical features strongly suggesting bacterial LRTI in an otherwise healthy adult.** When symptom duration, fever pattern, and progression align with bacterial bronchopneumonia in a patient with no red flag features and no indication of pneumonia, a telehealth doctor may prescribe while advising on review triggers.

**Established patient with known recurrent bacterial bronchitis.** Patients with a documented history of recurrent bacterial chest infections, particularly those with underlying bronchiectasis or COPD, may have a clear clinical pattern that supports prescribing based on symptom recognition.

**Asthma exacerbation with infectious trigger and clinical suspicion of bacterial involvement.** When wheezing and worsening asthma control coincide with a productive change and systemic features, bacterial co-infection may be contributing and may warrant antibiotic treatment alongside bronchodilator optimisation.

In all cases, the decision is based on clinical probability and risk stratification - not patient preference or sputum colour.

Some presentations require physical examination, oxygen saturation measurement, imaging, or the ability to escalate rapidly. Telehealth is the wrong channel for these. An AHPRA-registered doctor assessing your chest infection will refer you to in-person care when:

**Pneumonia is suspected.** High fever with rigors, pleuritic chest pain, significant breathlessness, or systemic illness disproportionate to a simple chest infection raises the possibility of pneumonia. Confirming pneumonia requires auscultation and often a chest X-ray. Telehealth cannot safely exclude or diagnose CAP in moderate-to-severe presentations.

**Breathlessness at rest or significant dyspnoea.** Any significant breathlessness beyond what the cough alone explains is a red flag. Without the ability to measure your respiratory rate accurately or assess accessory muscle use and work of breathing, telehealth cannot safely manage this presentation.

**SpO2 concerns.** Oxygen saturation below 94% on room air is a significant clinical finding requiring in-person assessment, supplemental oxygen consideration, and often hospital evaluation. Telehealth has no capacity to measure or monitor SpO2.

**High fever with confusion or altered mental state.** Confusion plus high fever plus respiratory illness is a potential sepsis presentation. This is an emergency - see below.

**Elderly patients (65 or over) with LRTI.** Older patients have reduced physiological reserve, are more likely to deteriorate rapidly, and have higher mortality from CAP. CURB-65 risk stratification is not reliably applied via telehealth for this group. In-person assessment is appropriate.

**Immunocompromised patients.** Patients on oral corticosteroids, chemotherapy, biologics, or with conditions such as HIV are at elevated risk of atypical organisms, rapid deterioration, and complications. These presentations require in-person assessment.

**No improvement after 48-72 hours of watchful waiting.** If you have followed a period of symptomatic management for a presumed viral chest infection and are not improving, in-person review allows auscultation and examination to determine whether the clinical picture has changed.

**Underlying significant comorbidities.** Significant heart failure, severe COPD with known low baseline oxygen saturation, active malignancy, or recent hospitalisation all warrant in-person evaluation rather than telehealth management for a new chest infection.

When antibiotic prescribing is clinically appropriate, the choice follows Australian Therapeutic Guidelines:

**Community-acquired pneumonia (outpatient, low-risk):** Amoxicillin 1g three times daily for 5-7 days is first-line for typical CAP where S. pneumoniae is the likely causative organism. For penicillin-allergic patients, doxycycline is an alternative. Coverage for atypical organisms is added if these cannot be excluded clinically - a combination of amoxicillin plus doxycycline, or roxithromycin alone for milder atypical presentations.

**Atypical pneumonia (Mycoplasma, Chlamydophila):** Doxycycline 100mg twice daily is the standard first-line choice, effective against both Mycoplasma pneumoniae and Chlamydophila pneumoniae. Roxithromycin is an alternative macrolide used in Australian practice. These agents are ineffective against Streptococcus pneumoniae, so the distinction between typical and atypical CAP matters clinically.

**COPD exacerbation with purulent sputum:** Amoxicillin 500mg three times daily, doxycycline 200mg on day 1 then 100mg daily, or cefalexin 500mg four times daily are all appropriate options depending on allergy history, recent antibiotic use, and local resistance patterns.

**Acute bacterial bronchitis (selected cases, underlying lung disease):** Amoxicillin or doxycycline at standard doses. Duration is typically 5-7 days. In otherwise healthy adults without underlying lung disease, antibiotic prescribing for acute bronchitis is generally not appropriate regardless of sputum colour.

All antibiotic prescribing decisions account for your allergy history and any recent antibiotic use, which can select for resistance and affect which first-line agents remain appropriate.

Understanding the natural history of chest infections helps you know whether things are progressing normally or whether review is needed.

**Viral acute bronchitis:** Cough onset within days of a viral URTI. Productive cough peaks around days 3-7, then gradually settles. Total cough duration is typically 2-3 weeks, occasionally up to 4 weeks. Systemic symptoms (fever, myalgia, fatigue) usually resolve within 5-7 days. If cough is the only persisting symptom past week 2 and is gradually improving, this is within the expected range.

**Bacterial LRTI treated with antibiotics:** Fever typically begins to resolve within 24-48 hours of starting appropriate antibiotics. Sputum production generally decreases within 3-4 days. Cough may persist for 1-2 weeks after antibiotic completion. Fatigue and generalised weakness can persist for 2-3 weeks after pneumonia.

**Red flag: no improvement at 48-72 hours.** If systemic symptoms (fever, significant breathlessness) are not improving within 48-72 hours of starting antibiotics, review is warranted. Either the antibiotic is not covering the causative organism, the diagnosis is incorrect (viral, not bacterial), or there is a complication developing.

Some chest infection presentations are emergencies. Call triple zero (000) immediately if you or someone else has:

• **Severe breathlessness** - unable to complete full sentences, using neck or shoulder muscles to breathe, breathing very rapidly
• **Lips, fingernails, or skin turning blue** (cyanosis) - indicates severe oxygen deficiency
• **High fever combined with confusion or altered consciousness** - potential sepsis
• **Chest pain that is severe, crushing, or radiating to the arm or jaw** - may indicate cardiac involvement rather than (or alongside) respiratory infection
• **Rapid deterioration** - significant worsening over minutes to hours, particularly in someone with known COPD or heart failure
• **No response to reliever inhaler in an asthma patient** with worsening breathlessness

Do not wait to book a telehealth appointment for any of the above. Call 000.

If your presentation is appropriate for telehealth assessment - you are an otherwise healthy adult with symptoms suggesting bacterial LRTI, or you have known COPD with a typical exacerbation pattern - the process is straightforward.

Complete an online doctor consultation describing your symptoms in detail: when the cough started, how it has progressed, whether you have fever and how high, whether you have breathlessness, your sputum description, and any relevant medical history including smoking history, lung conditions, allergies, and recent antibiotic use. An AHPRA-registered doctor reviews your case and either:

• Prescribes antibiotics and sends an eScript to your phone if bacterial infection is clinically likely and the presentation is appropriate for remote management
• Recommends symptomatic management if the presentation is consistent with viral bronchitis not requiring antibiotics
• Refers you for in-person assessment if your symptoms suggest pneumonia, include red flag features, or your risk profile makes telehealth management inappropriate

If antibiotics are prescribed, the eScript is a digital token sent by SMS that you take to any Australian pharmacy. PBS pricing applies with a Medicare card. You do not need to fill it at a specific pharmacy.

Being referred for in-person care is not a failure of the service. It is the system working correctly - keeping you safe when remote assessment cannot provide the clinical certainty needed to prescribe or manage your infection safely.